Atreca Inc (BCEL)
OTHER OTC:BCEL
US Market
Holding BCEL?
Track your performance easily

Atreca (BCEL) Stock Forecast & Price Target

469 Followers
See the Price Targets and Ratings of:

BCEL Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Atreca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BCEL Stock 12 Month Forecast

There Are No Analyst Ratings for BCEL In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

BCEL Financial Forecast

BCEL Earnings Forecast

Next quarter’s earnings estimate for BCEL is -$0.15 with a range of -$0.15 to -$0.15. The previous quarter’s EPS was ―. BCEL beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year BCEL has Outperformed its overall industry.
Next quarter’s earnings estimate for BCEL is -$0.15 with a range of -$0.15 to -$0.15. The previous quarter’s EPS was ―. BCEL beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year BCEL has Outperformed its overall industry.

BCEL Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity
$2
Buy
2122.22%
Upside
Reiterated
11/15/23
Analysts Offer Insights on Healthcare Companies: Atreca (NASDAQ: BCEL), Lucid Diagnostics (NASDAQ: LUCD) and Vertex Pharmaceuticals (NASDAQ: VRTX)
TD Cowen
Buy
Reiterated
11/14/23
TD Cowen Remains a Buy on Atreca (BCEL)
Stifel Nicolaus
$1
Hold
1011.11%
Upside
Reiterated
08/15/23
Analysts' Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (NASDAQ: ALXO), Atreca (NASDAQ: BCEL) and Sientra (NASDAQ: SIEN)
Wedbush
$1
Hold
1011.11%
Upside
Downgraded
08/14/23
Atreca downgraded to Neutral from Outperform at WedbushAtreca downgraded to Neutral from Outperform at Wedbush
H.C. Wainwright
Hold
Downgraded
08/11/23
Atreca downgraded to Neutral from Buy at H.C. WainwrightAtreca downgraded to Neutral from Buy at H.C. Wainwright

Best Analysts Covering Atreca

Which Analyst Should I Follow If I Want to Buy BCEL and Sell After:
1 Month
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
-2.99%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of -2.99% per trade.
3 Months
xxx
Success Rate
4/13 ratings generated profit
31%
Average Return
-10.36%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 30.77% of your transactions generating a profit, with an average return of -10.36% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
2/13 ratings generated profit
15%
Average Return
-46.21%
reiterated a buy rating 12 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -46.21% per trade.
2 Years
xxx
Success Rate
0/13 ratings generated profit
0%
Average Return
-83.16%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -83.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCEL Analyst Recommendation Trends

Rating
Mar 23
May 23
Jun 23
Aug 23
Nov 23
Strong Buy
7
9
9
5
2
Buy
0
0
0
0
1
Hold
1
1
1
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
10
10
9
7
In the current month, BCEL has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BCEL average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BCEL Stock Forecast FAQ

What is BCEL’s average 12-month price target, according to analysts?
Currently, no data Available
What is BCEL’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for BCEL, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is BCEL a Buy, Sell or Hold?
      Currently, no data Available
      What is Atreca Inc’s price target?
      Currently, no data Available
      What do analysts say about Atreca Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of BCEL?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis